Details of Disease

General Information of Disease (ID: DISC905E)

Disease Name Neuropathic pain
Disease Class 8E43: General pain disorder
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISC905E: Neuropathic pain
ICD Code
ICD-11
ICD-11: 8E43.0
Disease Identifiers
MedGen ID
811414
HPO ID
HP:6000040
SNOMED CT ID
247398009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Capsaicin DMGMF6V Approved Small molecular drug [1]
Tiapride DMN6CAG Approved Small molecular drug [2]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 45 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AMG 386 DMQJXL4 Phase 3 Small molecular drug [2]
AXS-02 DMNJ6R1 Phase 3 NA [3]
Bicifadine DM42GP9 Phase 3 Small molecular drug [2]
Fasinumab DM5PRLA Phase 3 NA [3]
NKTR-181 DM45DS8 Phase 3 NA [3]
Ralfinamide DMUNMY0 Phase 3 Small molecular drug [2]
REL-1017 DM34GOF Phase 3 Small molecular drug [4]
Tanezumab DMJKWMA Phase 3 Monoclonal antibody [3]
AGN-199981 DMP5Y1A Phase 2 NA [2]
ALLOD-2 DMCITS3 Phase 2 NA [3]
ASP-8477 DMBZQS7 Phase 2 NA [5]
Ataciguat DM35KDA Phase 2 Small molecular drug [6]
AV-101 DMN7VK1 Phase 2 NA [7]
CHF-3381 DMQ2O8V Phase 2 Small molecular drug [8]
Cibinetide DMCFLRH Phase 2 NA [9]
Cizolirtine DMOFTRE Phase 2 Small molecular drug [2]
CMX-020 DM43QM3 Phase 2 NA [3]
CNS-5161 DM16KJ3 Phase 2 Small molecular drug [2]
CNSB-001 DM2PEU5 Phase 2 NA [10]
Dimiracetam DM96NHM Phase 2 Small molecular drug [11]
DWP-05195 DMQKU2F Phase 2 NA [12]
Fadolmidine DM6RKG3 Phase 2 Small molecular drug [3]
KHK-6188 DMF6CTI Phase 2 NA [13]
LY-545694 DMMSBW5 Phase 2 NA [14]
NS 1209 DM9EFH0 Phase 2 Small molecular drug [15]
Prosaptide TX14(A) DME25TI Phase 2 NA [16]
Resiniferatoxin DMP62L5 Phase 2 Small molecular drug [17]
SLC-022 DM212MH Phase 2 NA [18]
Spiroglumide DM7NJWY Phase 2 Small molecular drug [2]
VX-150 DMGDB21 Phase 2 NA [3]
ABX-1431 DM9SYVJ Phase 1 NA [3]
ACV-1 DMRDY0G Phase 1 NA [2]
AZD-6088 DM0WCR4 Phase 1 Small molecular drug [19]
BI-660848 DMD9ZHH Phase 1 NA [20]
CC8464 DMILHMC Phase 1 NA [21]
DSP-2230 DM0WTMD Phase 1 NA [21]
DSP-3905 DMYHU24 Phase 1 NA [21]
DWJ-208 DMQKDJZ Phase 1 NA [21]
GPI-16072 DM0ZQ48 Phase 1 Small molecular drug [22]
LX9211 DMO548K Phase 1 NA [3]
NitroSense PA6 DM5CRRD Phase 1 NA [23]
S-117957 DMK6X39 Phase 1 NA [24]
SEP-228432 DMF89ZT Phase 1 NA [25]
VBY- 036 DMULRYC Phase 1 NA [26]
VBY-129 DM4YIWK Phase 1 NA [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 45 Drug(s)
This Disease is Treated as An Indication in 237 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Patented NA [27]
Azaindazole amide derivative 1 DMJWH4B Patented NA [27]
Bicyclic heteroaryl benzamide derivative 1 DMTBWC9 Patented NA [27]
Bicyclic heteroaryl benzamide derivative 2 DM5MT4R Patented NA [27]
Bicyclic heteroaryl benzamide derivative 3 DM54EV2 Patented NA [27]
Bicyclic heteroaryl benzamide derivative 4 DMUBDYG Patented NA [27]
Bicyclic heteroaryl benzamide derivative 5 DMFOVPT Patented NA [27]
Bicyclic heteroaryl benzamide derivative 6 DMQGYWV Patented NA [27]
Bicyclic heteroaryl benzamide derivative 7 DMM1LKF Patented NA [27]
Bicyclic heteroaryl benzamide derivative 8 DMVBQJ1 Patented NA [27]
Bicyclic heteroaryl benzamide derivative 9 DMGONY4 Patented NA [27]
Five membered heterocyclic benzamide derivative 1 DMPFAST Patented NA [27]
Five membered heterocyclic benzamide derivative 2 DM4U63E Patented NA [27]
Five membered heterocyclic benzamide derivative 3 DMUS4Z0 Patented NA [27]
Imidazo pyridine derivative 1 DMCXHGW Patented NA [27]
Isoquinoline derivative 1 DMR0Y3K Patented Small molecular drug [28]
Isoquinoline derivative 2 DMRHBLD Patented Small molecular drug [28]
Isoquinoline derivative 3 DM4R1MK Patented Small molecular drug [28]
N-(phenylpyrazolyl)benzamide derivative 1 DM0ZJX7 Patented NA [27]
N-acylpiperidine ether derivative 1 DM5GCUR Patented NA [27]
N-acylpiperidine ether derivative 2 DM02RQ4 Patented NA [27]
N-acylpiperidine ether derivative 3 DMXWE5R Patented NA [27]
N-acylpiperidine ether derivative 4 DMBUQDR Patented NA [27]
N-acylpiperidine ether derivative 5 DMQ2MKT Patented NA [27]
N-acylpiperidine ether derivative 6 DMAS01P Patented NA [27]
N-acylpiperidine ether derivative 7 DMCJR4N Patented NA [27]
N-acylpyrrolidine ether derivative 1 DMQ4ULC Patented NA [27]
N-acylpyrrolidine ether derivative 2 DMK4Y71 Patented NA [27]
PMID25666693-Compound-1 DMEL1WX Patented Small molecular drug [29]
PMID25666693-Compound-10 DMQP3TD Patented Small molecular drug [29]
PMID25666693-Compound-100 DMYTZFP Patented Small molecular drug [29]
PMID25666693-Compound-101 DMNOD4A Patented Small molecular drug [29]
PMID25666693-Compound-102 DM0OY5D Patented Small molecular drug [29]
PMID25666693-Compound-103 DM8DZA6 Patented Small molecular drug [29]
PMID25666693-Compound-104 DMYCT5B Patented Small molecular drug [29]
PMID25666693-Compound-105 DMV509A Patented Small molecular drug [29]
PMID25666693-Compound-106 DMEG8CB Patented Small molecular drug [29]
PMID25666693-Compound-107 DMB2RML Patented Small molecular drug [29]
PMID25666693-Compound-108 DMN0FCA Patented Small molecular drug [29]
PMID25666693-Compound-109 DMWGIS7 Patented Small molecular drug [29]
PMID25666693-Compound-11 DM9HOM6 Patented Small molecular drug [29]
PMID25666693-Compound-110 DMNGD2S Patented Small molecular drug [29]
PMID25666693-Compound-111 DMNKW1E Patented Small molecular drug [29]
PMID25666693-Compound-112 DMQOSH5 Patented Small molecular drug [29]
PMID25666693-Compound-113 DM02O5V Patented Small molecular drug [29]
PMID25666693-Compound-114 DMA9YDK Patented Small molecular drug [29]
PMID25666693-Compound-115 DMF5ODZ Patented Small molecular drug [29]
PMID25666693-Compound-116 DMNEBXL Patented Small molecular drug [29]
PMID25666693-Compound-117 DMN9LDH Patented Small molecular drug [29]
PMID25666693-Compound-118 DMBIQMS Patented Small molecular drug [29]
PMID25666693-Compound-119 DMD0WIA Patented Small molecular drug [29]
PMID25666693-Compound-12 DMVSFNE Patented Small molecular drug [29]
PMID25666693-Compound-120 DMVREIM Patented Small molecular drug [29]
PMID25666693-Compound-121 DMC1QDB Patented Small molecular drug [29]
PMID25666693-Compound-122 DMR63O2 Patented Small molecular drug [29]
PMID25666693-Compound-123 DM9358G Patented Small molecular drug [29]
PMID25666693-Compound-124 DM6ODU7 Patented Small molecular drug [29]
PMID25666693-Compound-125 DMR0WM1 Patented Small molecular drug [29]
PMID25666693-Compound-126 DMKN72Y Patented Small molecular drug [29]
PMID25666693-Compound-127 DMCE6MB Patented Small molecular drug [29]
PMID25666693-Compound-128 DM6QHGV Patented Small molecular drug [29]
PMID25666693-Compound-129 DM74NBY Patented Small molecular drug [29]
PMID25666693-Compound-13 DMI0YWU Patented Small molecular drug [29]
PMID25666693-Compound-130 DMIX1K0 Patented Small molecular drug [29]
PMID25666693-Compound-131 DML7SYH Patented Small molecular drug [29]
PMID25666693-Compound-132 DMHQM8W Patented Small molecular drug [29]
PMID25666693-Compound-133 DMHEPR3 Patented Small molecular drug [29]
PMID25666693-Compound-134 DM2WJKR Patented Small molecular drug [29]
PMID25666693-Compound-135 DMYZVPD Patented Small molecular drug [29]
PMID25666693-Compound-136 DMPY1QC Patented Small molecular drug [29]
PMID25666693-Compound-137 DMZ7LAO Patented Small molecular drug [29]
PMID25666693-Compound-138 DMJLFEN Patented Small molecular drug [29]
PMID25666693-Compound-139 DMLMEPI Patented Small molecular drug [29]
PMID25666693-Compound-14 DM3D4RI Patented Small molecular drug [29]
PMID25666693-Compound-140 DMVQU9T Patented Small molecular drug [29]
PMID25666693-Compound-141 DMQGTYE Patented Small molecular drug [29]
PMID25666693-Compound-142 DMFKN1O Patented Small molecular drug [29]
PMID25666693-Compound-143 DMJP0NB Patented Small molecular drug [29]
PMID25666693-Compound-144 DMCXELD Patented Small molecular drug [29]
PMID25666693-Compound-145 DMP89E4 Patented Small molecular drug [29]
PMID25666693-Compound-146 DMLE5BK Patented Small molecular drug [29]
PMID25666693-Compound-147 DMG1SYN Patented Small molecular drug [29]
PMID25666693-Compound-148 DM0EYON Patented Small molecular drug [29]
PMID25666693-Compound-149 DMPU19H Patented Small molecular drug [29]
PMID25666693-Compound-15 DM1G6AE Patented Small molecular drug [29]
PMID25666693-Compound-150 DMHMEFY Patented Small molecular drug [29]
PMID25666693-Compound-151 DM5CY86 Patented Small molecular drug [29]
PMID25666693-Compound-152 DM27154 Patented Small molecular drug [29]
PMID25666693-Compound-153 DM1FTV6 Patented Small molecular drug [29]
PMID25666693-Compound-154 DMKNU0Z Patented Small molecular drug [29]
PMID25666693-Compound-155 DMZLB07 Patented Small molecular drug [29]
PMID25666693-Compound-156 DMTVAUP Patented Small molecular drug [29]
PMID25666693-Compound-157 DME8LUY Patented Small molecular drug [29]
PMID25666693-Compound-158 DM2BTCU Patented Small molecular drug [29]
PMID25666693-Compound-159 DM74OGS Patented Small molecular drug [29]
PMID25666693-Compound-16 DM6SL9D Patented Small molecular drug [29]
PMID25666693-Compound-160 DM2KTAB Patented Small molecular drug [29]
PMID25666693-Compound-161 DM06IWA Patented Small molecular drug [29]
PMID25666693-Compound-162 DMXS5WY Patented Small molecular drug [29]
PMID25666693-Compound-17 DMRK1W7 Patented Small molecular drug [29]
PMID25666693-Compound-18 DMKU6C3 Patented Small molecular drug [29]
PMID25666693-Compound-19 DM63UM8 Patented Small molecular drug [29]
PMID25666693-Compound-2 DMERD39 Patented Small molecular drug [29]
PMID25666693-Compound-20 DM3I90D Patented Small molecular drug [29]
PMID25666693-Compound-21 DMUXO47 Patented Small molecular drug [29]
PMID25666693-Compound-22 DMHPW3X Patented Small molecular drug [29]
PMID25666693-Compound-23 DMJ3YDT Patented Small molecular drug [29]
PMID25666693-Compound-24 DMUMYKX Patented Small molecular drug [29]
PMID25666693-Compound-25 DMI8CB3 Patented Small molecular drug [29]
PMID25666693-Compound-26 DMQBFI2 Patented Small molecular drug [29]
PMID25666693-Compound-27 DMKHO8T Patented Small molecular drug [29]
PMID25666693-Compound-28 DM7T962 Patented Small molecular drug [29]
PMID25666693-Compound-29 DM02D1B Patented Small molecular drug [29]
PMID25666693-Compound-3 DMN692C Patented Small molecular drug [29]
PMID25666693-Compound-30 DMC3DT7 Patented Small molecular drug [29]
PMID25666693-Compound-31 DM853Y7 Patented Small molecular drug [29]
PMID25666693-Compound-32 DM58Z4M Patented Small molecular drug [29]
PMID25666693-Compound-33 DMW7981 Patented Small molecular drug [29]
PMID25666693-Compound-34 DMWGAQU Patented Small molecular drug [29]
PMID25666693-Compound-35 DMG9CPH Patented Small molecular drug [29]
PMID25666693-Compound-36 DMWVR81 Patented Small molecular drug [29]
PMID25666693-Compound-37 DMSR218 Patented Small molecular drug [29]
PMID25666693-Compound-38 DMBW36Y Patented Small molecular drug [29]
PMID25666693-Compound-39 DML3KHF Patented Small molecular drug [29]
PMID25666693-Compound-4 DMBD9S5 Patented Small molecular drug [29]
PMID25666693-Compound-40 DM58QW1 Patented Small molecular drug [29]
PMID25666693-Compound-41 DML76MF Patented Small molecular drug [29]
PMID25666693-Compound-42 DM6I49E Patented Small molecular drug [29]
PMID25666693-Compound-43 DMTN25V Patented Small molecular drug [29]
PMID25666693-Compound-44 DM0I72B Patented Small molecular drug [29]
PMID25666693-Compound-45 DMVDKXY Patented Small molecular drug [29]
PMID25666693-Compound-46 DM0MEXT Patented Small molecular drug [29]
PMID25666693-Compound-47 DMHBN5M Patented Small molecular drug [29]
PMID25666693-Compound-48 DMEVL0S Patented Small molecular drug [29]
PMID25666693-Compound-49 DM67DEG Patented Small molecular drug [29]
PMID25666693-Compound-5 DM53PBG Patented Small molecular drug [29]
PMID25666693-Compound-50 DM4GUZO Patented Small molecular drug [29]
PMID25666693-Compound-51 DM3KSV9 Patented Small molecular drug [29]
PMID25666693-Compound-52 DMQPOGC Patented Small molecular drug [29]
PMID25666693-Compound-53 DMKCARH Patented Small molecular drug [29]
PMID25666693-Compound-54 DMLW95Y Patented Small molecular drug [29]
PMID25666693-Compound-55 DMPE7M8 Patented Small molecular drug [29]
PMID25666693-Compound-56 DM82BAM Patented Small molecular drug [29]
PMID25666693-Compound-57 DMQRFXT Patented Small molecular drug [29]
PMID25666693-Compound-58 DMJEH0F Patented Small molecular drug [29]
PMID25666693-Compound-59 DMLI1YR Patented Small molecular drug [29]
PMID25666693-Compound-6 DMC5W1Y Patented Small molecular drug [29]
PMID25666693-Compound-60 DM2C58A Patented Small molecular drug [29]
PMID25666693-Compound-61 DM0B578 Patented Small molecular drug [29]
PMID25666693-Compound-62 DMDMFJG Patented Small molecular drug [29]
PMID25666693-Compound-63 DM6DFAK Patented Small molecular drug [29]
PMID25666693-Compound-64 DMDWH8T Patented Small molecular drug [29]
PMID25666693-Compound-65 DM1A0GT Patented Small molecular drug [29]
PMID25666693-Compound-66 DMD13OS Patented Small molecular drug [29]
PMID25666693-Compound-67 DMPV9L2 Patented Small molecular drug [29]
PMID25666693-Compound-68 DM87HTO Patented Small molecular drug [29]
PMID25666693-Compound-69 DMIPFO3 Patented Small molecular drug [29]
PMID25666693-Compound-7 DMNTVFH Patented Small molecular drug [29]
PMID25666693-Compound-70 DMEPYGQ Patented Small molecular drug [29]
PMID25666693-Compound-71 DM4VAQ3 Patented Small molecular drug [29]
PMID25666693-Compound-72 DMW8XD2 Patented Small molecular drug [29]
PMID25666693-Compound-73 DM9LZJ5 Patented Small molecular drug [29]
PMID25666693-Compound-74 DM80E3F Patented Small molecular drug [29]
PMID25666693-Compound-75 DMNATSQ Patented Small molecular drug [29]
PMID25666693-Compound-76 DMYH429 Patented Small molecular drug [29]
PMID25666693-Compound-77 DM05D48 Patented Small molecular drug [29]
PMID25666693-Compound-78 DMQI1YN Patented Small molecular drug [29]
PMID25666693-Compound-79 DMTQ26G Patented Small molecular drug [29]
PMID25666693-Compound-8 DMZQ6HC Patented Small molecular drug [29]
PMID25666693-Compound-80 DMB56LS Patented Small molecular drug [29]
PMID25666693-Compound-81 DM5ZELW Patented Small molecular drug [29]
PMID25666693-Compound-82 DM1MZ70 Patented Small molecular drug [29]
PMID25666693-Compound-83 DM2ZVXD Patented Small molecular drug [29]
PMID25666693-Compound-84 DM4QYIJ Patented Small molecular drug [29]
PMID25666693-Compound-85 DMGVU7M Patented Small molecular drug [29]
PMID25666693-Compound-86 DMFZ3S4 Patented Small molecular drug [29]
PMID25666693-Compound-87 DMAV4XY Patented Small molecular drug [29]
PMID25666693-Compound-88 DMT9EJL Patented Small molecular drug [29]
PMID25666693-Compound-89 DM6RQKH Patented Small molecular drug [29]
PMID25666693-Compound-9 DM8A4B5 Patented Small molecular drug [29]
PMID25666693-Compound-90 DM26NQE Patented Small molecular drug [29]
PMID25666693-Compound-91 DMXU3IE Patented Small molecular drug [29]
PMID25666693-Compound-92 DMRGOZ8 Patented Small molecular drug [29]
PMID25666693-Compound-93 DMM5EI4 Patented Small molecular drug [29]
PMID25666693-Compound-94 DMHREX9 Patented Small molecular drug [29]
PMID25666693-Compound-95 DMFNB1T Patented Small molecular drug [29]
PMID25666693-Compound-96 DME3NTB Patented Small molecular drug [29]
PMID25666693-Compound-97 DMHJOP7 Patented Small molecular drug [29]
PMID25666693-Compound-98 DM2ZR8M Patented Small molecular drug [29]
PMID25666693-Compound-99 DMOISDH Patented Small molecular drug [29]
PMID28270021-Compound-WO2010077680 103 DM437ZC Patented NA [27]
PMID28270021-Compound-WO2010077680 109 DMNUA21 Patented NA [27]
PMID28270021-Compound-WO2010077680 201 DMQAZMC Patented NA [27]
PMID28270021-Compound-WO2010077680 481 DM6VAS2 Patented NA [27]
PMID28270021-Compound-WO2010077680 495 DMQ9CBS Patented NA [27]
PMID28270021-Compound-WO2010077680 803 DM6TJU0 Patented NA [27]
PMID28270021-Compound-WO2010077680 811 DM47FNS Patented NA [27]
PMID28270021-Compound-WO2013009582Example16 DMVS7CJ Patented NA [27]
PMID28270021-Compound-WO2013009582Example76 DMQK4IX Patented NA [27]
PMID28270021-Compound-WO2013161919Example85-117 DM2XKTB Patented NA [27]
PMID28270021-Compound-WO2014078408Example1 DMO02EL Patented NA [27]
PMID28270021-Compound-WO2014078408Example26 DMVCBSK Patented NA [27]
PMID28270021-Compound-WO2014129431Example8-1 DMKO4ZH Patented NA [27]
PMID28270021-Compound-WO2014152663 701 DMA04P6 Patented NA [27]
PMID28270021-Compound-WO2015042088Example11 DM16URY Patented NA [27]
PMID28270021-Compound-WO2015042088Example12 DMOZHGU Patented NA [27]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Patented NA [27]
PMID28270021-Compound-WO2016054807Example1 DMD5QEL Patented NA [27]
PMID28270021-Compound-WO2016054807Example112 DMW2ZRM Patented NA [27]
PMID28270021-Compound-WO2016054807Example71 DMREZ9I Patented NA [27]
PMID28270021-Compound-WO2016054807Example80 DMPI86D Patented NA [27]
PMID28270021-Compound-WO2016054807Example82 DM9ADSN Patented NA [27]
PMID29334795-Compound-22 DM8N10A Patented Small molecular drug [30]
Pyrazolo[1,5-a]pyridine derivative 1 DMH1W89 Patented NA [27]
Pyrazolo[1,5-a]pyridine derivative 2 DMLS827 Patented NA [27]
Pyrazolo[4,3-c]pyridine derivative 1 DMHRUIZ Patented NA [27]
Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 DMTM82B Patented NA [27]
Pyrido[3,2-d]pyrimidine derivative 2 DMRHAU4 Patented NA [27]
Pyrido[3,2-d]pyrimidine derivative 3 DM6D1XR Patented NA [27]
Pyrrolo[2,3-b]pyridine derivative 1 DMVKCQU Patented NA [27]
Pyrrolo[2,3-b]pyridine derivative 2 DM7IPWB Patented NA [27]
Pyrrolo[2,3-b]pyridine derivative 3 DMCYOL7 Patented NA [27]
Pyrrolo[2,3-d]pyrimidine derivative 3 DMTX1G4 Patented NA [27]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Patented NA [27]
Pyrrolo[3,2-c]pyridine derivative 1 DMKF8HI Patented NA [27]
Six-membered heterocyclic benzamide derivative 1 DMYFK85 Patented NA [27]
Six-membered heterocyclic benzamide derivative 2 DMX6AKV Patented NA [27]
Six-membered heterocyclic benzamide derivative 3 DMEGVD4 Patented NA [27]
Six-membered heterocyclic benzamide derivative 4 DMB0D1H Patented NA [27]
Six-membered heterocyclic benzamide derivative 5 DM0GTUH Patented NA [27]
Six-membered heterocyclic benzamide derivative 6 DMZU96C Patented NA [27]
Six-membered heterocyclic benzamide derivative 7 DM15AFI Patented NA [27]
Tri-substituted urea derivative 1 DMHGRTX Patented NA [27]
Tri-substituted urea derivative 2 DMUVPR8 Patented NA [27]
Triazolo[4,3-b]pyridazine derivative 2 DMMJ1FN Patented NA [27]
Tricyclic phytocannabinoid derivative 1 DM94NZF Patented Small molecular drug [28]
Tricyclic phytocannabinoid derivative 2 DM7YVQL Patented Small molecular drug [28]
------------------------------------------------------------------------------------
⏷ Show the Full List of 237 Drug(s)
This Disease is Treated as An Indication in 16 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
GW-406381 DMJ4KQS Discontinued in Phase 3 Small molecular drug [2]
EVT-101 DMOYMGV Discontinued in Phase 2 Small molecular drug [31]
GSK-644784 DMUC9OS Discontinued in Phase 2 Small molecular drug [2]
GW-493838 DMZ2OBD Discontinued in Phase 2 Small molecular drug [2]
PF-4480682 DMWYJHC Discontinued in Phase 2 NA [32]
ASP9226 DMSI8PZ Discontinued in Phase 1 NA [33]
AZD-9272 DMYSBN3 Discontinued in Phase 1 Small molecular drug [34]
PF-2393296 DM5R2MG Discontinued in Phase 1 NA [35]
T-62 DMQVLZH Discontinued in Phase 1 Small molecular drug [2]
DLX-0110 DMKIYZL Terminated NA [38]
E-2070 DMAU0FP Terminated Small molecular drug [39]
LY467711 DM0TV9L Terminated Small molecular drug [40]
LY525327 DMPNMAR Terminated Small molecular drug [40]
NSL-036 DMPG703 Terminated NA [41]
PRS-639058 DMNK2I0 Terminated NA [42]
SRSC-355 DMFLPU5 Terminated NA [43]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Drug(s)
This Disease is Treated as An Indication in 2 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AD-529 DMBI1H2 Preclinical NA [36]
NSL-105 DMSYQZU Preclinical NA [37]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 27 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AC-101 DMXTWGU Investigative Small molecular drug [44]
AF-3473 DM6B9CK Investigative NA [45]
AQU-010 DM3RE5C Investigative NA [44]
ASP-8370 DMFWTOP Investigative NA [46]
AZM-1 DMWNW30 Investigative NA [44]
DD-20207 DM8PVLP Investigative NA [44]
DWJ-207 DMOOQEE Investigative NA [44]
EpiCept DMFMWA7 Investigative NA [47]
GABA mimetics DM5HD53 Investigative NA [44]
GP-1100 DM6GMZZ Investigative NA [44]
HZ-166 DMLU6VM Investigative NA [48]
IG-CN-023 DM5CU0W Investigative NA [44]
MDA-19 DMEUWB8 Investigative Small molecular drug [49]
NCX-1236 DM9VUK1 Investigative NA [44]
NKTR-171 DMO3FPZ Investigative NA [44]
NT-001 DMFC9SF Investigative NA [44]
NT-13317 DM1JQF4 Investigative NA [44]
RAP-103 DM961JG Investigative NA [50]
RQ-00203078 DM83THZ Investigative NA [51]
SKL-NP2 DM4FE7O Investigative NA [44]
T-270 DMAMWMA Investigative NA [44]
THA-904 DMQSO7V Investigative NA [52]
TRL-382 DMU3E1M Investigative NA [53]
VBY- 285 DM8ACIF Investigative NA [54]
VER-156084 DMFZMA2 Investigative Small molecular drug [55]
XT-101 DM7BTNF Investigative NA [56]
YT-1006 DMADJX9 Investigative NA [44]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2486).
2 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT03638869) Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone). U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5141).
7 ClinicalTrials.gov (NCT02484456) Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder.
8 Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007 Sep;10(9):636-44.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029018)
11 ClinicalTrials.gov (NCT01135251) Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy. U.S. National Institutes of Health.
12 ClinicalTrials.gov (NCT01557010) Evaluate the Efficacy and Safety of DWP05195 in Subjects With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
13 ClinicalTrials.gov (NCT01544296) A Comparative Study of KHK6188. U.S. National Institutes of Health.
14 ClinicalTrials.gov (NCT00785577) A Study for Treatment of Pain in Patients With Diabetic Neuropathy.. U.S. National Institutes of Health.
15 The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6067).
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2491).
18 ClinicalTrials.gov (NCT00813826) Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia. U.S. National Institutes of Health.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7822).
20 ClinicalTrials.gov (NCT01145014) To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution(Powder in Bottle).. U.S. National Institutes of Health.
21 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
22 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
23 Clinical pipeline report, company report or official report of NOLabs Ab.
24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035863)
25 ClinicalTrials.gov (NCT01531972) A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT01892891) Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing. U.S. National Institutes of Health.
27 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
28 Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56.
29 Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318.
30 Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023880)
32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025530)
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035276)
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6439).
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027949)
36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022365)
37 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026403)
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019520)
39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019940)
40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015556)
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022884)
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021026)
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018179)
44 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507).
47 Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108.
48 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57).
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59).
51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500).
52 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 685).
53 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1375).
54 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
55 Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4.
56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900).
57 A Phase III Randomized, Placebo-Controlled Study of Topical Amitriptyline and Ketamine for Chemotherapy-Induced Peripheral Neuropathy (CIPN): A University of Rochester CCOP Study of 462 Cancer Survivors. Support Care Cancer. 2014 July; 22(7): 1807-1814.